Bulk-scale formulation of ready-to-use therapeutic doses of lutetium-177- prostrate-specific membrane antigen-617 at a centralized radiopharmacy setup

Lutetium-177-labeled prostate-specific membrane antigen (PSMA) inhibitor has emerged as a promising modality for targeted therapy of prostate carcinoma. Deployment of ready-to-use formulation of ¹⁷⁷Lu-PSMA-617 to nuclear medicine centers from a centralized radiopharmacy setup would facilitate extensive utility of the radiopharmaceutical. The present article reports a detailed systematic study on regular bulk-scale production of ready-to-use doses of ¹⁷⁷Lu-PSMA-617 and optimization of storage parameters for its safe deployment to nuclear medicine centers. Development of an optimized protocol for bulk-scale formulation of ready-to-use ¹⁷⁷Lu-PSMA-617 utilizing moderate-specific activity ¹⁷⁷Lu has been successfully accomplished. The reported protocol would be very useful toward facilitating widespread clinical utilization of ¹⁷⁷Lu-PSMA-617 in the management of prostate cancer